Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Truist Financial Co. from $21.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Bank of America Co. from $14.00 to $12.00. They now have a "neutral" rating on the stock.MarketBeat
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Morgan Stanley from $11.00 to $7.00. They now have an "underweight" rating on the stock.MarketBeat
- Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswire
YMAB
Earnings
- 3/4/25 - Miss
YMAB
Sec Filings
- 3/11/25 - Form 4
- 3/11/25 - Form 4
- 3/7/25 - Form 144
- YMAB's page on the SEC website